The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | All things ibrutinib and CLL
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, describes when and how to use ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. Dr Scarfo goes on to give her thoughts on the long-term, real-world data available for ibrutinib.
